Pfizer signs generics deals with Indian firms
Pfizer has signed agreements with two India-based pharmaceutical companies as it seeks growth in generics and emerging markets.
Pfizer has signed agreements with two India-based pharmaceutical companies as it seeks growth in generics and emerging markets.
The deals with Aurobindo Pharma and Claris Lifesciences substantially increase Pfizer's offerings in medicines that have lost patent protection in markets around the world. Financial terms of the deals were not disclosed.
Pfizer will gain rights to 55 solid oral dose products and 5 sterile injectable products for patients in more than 70 emerging market countries in Latin America, Eastern Europe, Asia, Africa and the Middle East. The medicines include anti-infectives, and drugs for cardiovascular disease and disorders of the central nervous system. Pfizer will commercialise the 60 products in phases tailoring its approach for different regions.
Pfizer also expanded agreements with Aurobindo in developed markets, adding products in the US and Europe.
"The off-patent marketplace worldwide too often suffers from quality and supply reliability issues," said Jeff Kindler, chairman and chief executive of Pfizer. "With our broad established medicines portfolio and our world-class manufacturing capabilities, Pfizer is in an ideal position to supply high-quality medicines at affordable prices to people around the world."
